NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Other Events
Item8.01.
| Other Events. |
On May12, 2017, Nektar Therapeutics, a Delaware corporation
(Nektar), presented by way of an oral explanation at a meeting
held by the European Medicines Agencys Committee for Medicinal
Projects for Human Use (the CHMP) in support of Nektars
conditional approval marketing authorization application for
ONZEALDTM in the European Union (the MAA). At the
conclusion of the meeting, the CHMP informed Nektar that it
intended to refer the MAA to the CHMPs Scientific Advisory Group
(SAG) for a recommendation to the CHMP in support of its opinion
on the MAA. While no date has been set, Nektar currently expects
the SAG to meet this summer and then provide its recommendation
to the CHMP. Nektar looks forward to continuing to work
collaboratively with the CHMP to advance the review process for
the MAA.
About NEKTAR THERAPEUTICS (NASDAQ:NKTR)
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company’s drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection). NEKTAR THERAPEUTICS (NASDAQ:NKTR) Recent Trading Information
NEKTAR THERAPEUTICS (NASDAQ:NKTR) closed its last trading session down -0.59 at 18.95 with 1,217,150 shares trading hands.
